rilatine modified release 20 mg gél. lib. modif.
infectopharm arzneimittel und consilium gmbh - chlorhydrate de méthylphénidate 20 mg - gélule à libération modifiée - 20 mg - chlorhydrate de méthylphénidate 20 mg - methylphenidate
rilatine modified release 30 mg gél. lib. modif.
infectopharm arzneimittel und consilium gmbh - chlorhydrate de méthylphénidate 30 mg - gélule à libération modifiée - 30 mg - chlorhydrate de méthylphénidate 30 mg - methylphenidate
rilatine modified release 40 mg gél. lib. modif.
infectopharm arzneimittel und consilium gmbh - chlorhydrate de méthylphénidate 40 mg - gélule à libération modifiée - 40 mg - chlorhydrate de méthylphénidate 40 mg - methylphenidate
rilatine modified release 10 mg gél. lib. modif.
infectopharm arzneimittel und consilium gmbh - chlorhydrate de méthylphénidate 10 mg - gélule à libération modifiée - 10 mg - chlorhydrate de méthylphénidate 10 mg - methylphenidate
phesgo
roche registration gmbh - pertuzumab, trastuzumab - néoplasmes du sein - agents antinéoplasiques - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.
trodelvy
gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - agents antinéoplasiques - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
busulfan for injection solution
auro pharma inc - busulfan - solution - 60mg - busulfan 60mg - antineoplastic agents
rybrevant
janssen-cilag international n.v. - amivantamab - carcinome, poumon non à petites cellules - agents antinéoplasiques - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
padcev
astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - agents antinéoplasiques - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.
thiotépa pour injection usp poudre pour solution
sterimax inc - thiotépa - poudre pour solution - 15mg - thiotépa 15mg